ArticleNature communications2022
TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06062875 (Effects of TNF Blockade on Human BPH/LUTS), which is not on this map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of TNF Blockade on Human BPH/LUTS
Who cites it
56 citing papers in PubMed, 78 citations in OpenAlex.
- Macrophage pyroptosis drives luminal senescence and club-cell reprogramming in 5α-reductase inhibitor-treated prostatic hyperplasia.Experimental & molecular medicine · 2026Article
- Immune dysregulation in the prostates of C57BL/6The Journal of pathology · 2026Article
- Local growth hormone promotes benign prostatic hyperplasia.JCI insight · 2026Article
- T cell-derived CCL5 drives macrophage immunometabolic remodeling in chronic prostatitis via the CCR5-ERK-PKM2/HIF-1α axis.Redox biology · 2026Article
- High-Throughput Proteomic and Glycoproteomic Analyses in Benign Prostatic Hyperplasia.Journal of the American Society for Mass Spectrometry · 2026Article
- Prospective Metabolomic Cohort of 123,037 Men Reveals Lipid Mediators Linking Air Pollution to Benign Prostatic Hyperplasia.Environment & health (Washington, D.C.) · 2026Article
- Lipid and Foam Cell Accumulation as Novel Pathological Features of Benign Prostatic Hyperplasia.The Prostate · 2026Article
- JMJD3 modulates benign prostatic hyperplasia through epigenetic regulation of TGF-β1.Cell death & disease · 2026Article
- Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia.Prostate cancer and prostatic diseases · 2026Review
- SRD5A2 and emerging therapies in androgen-driven disorders.Nature reviews. Urology · 2026Review
- Global stagnation and misaligned priorities in BPH drug development: a 25-year landscape analysis of clinical trial registries.npj aging · 2026Article
- A single cell transcriptional profile of benign prostatic hyperplasia.Scientific reports · 2026Article
- Targeting ROCK1/YAP1 Axis Ameliorates Inflammation-Induced Prostatic Hyperplasia via Stabilising SIRT1-Dependent Mitochondrial Dynamics.Cell proliferation · 2026Article
- Integrated Single-Cell and Bulk RNA Sequencing Reveals Inflammatory Microenvironment and Glycolysis-Driven Epithelial Proliferation in Benign Prostatic Hyperplasia.Journal of inflammation research · 2026Article
- Integrated bulk and single-cell transcriptomics to develop an efferocytosis-related prognostic model for lung adenocarcinoma and validate the key gene LDHA.European journal of medical research · 2025Article
- The association between arthritis and the risk of lower urinary tract symptoms suggestive of benign prostate hyperplasia: evidence from the China Health and Retirement Longitudinal Study (CHARLS).Scientific reports · 2025Article
- Paeonol Ameliorates Benign Prostatic Hyperplasia via Suppressing Proliferation and NF-κB-In Silico and Experimental Studies.Pharmaceuticals (Basel, Switzerland) · 2025Article
- TNF-α modulates cell proliferation via SOX4/TGF-β/Smad signaling in benign prostatic hyperplasia.Cell death & disease · 2025Article
- The Combination ofThe world journal of men's health · 2025Article
- Immune repertoire profiling uncovers pervasive T cell clonal expansions in benign prostatic hyperplasia.The Journal of clinical investigation · 2025Article
Corrections and comments
- Commented on by
- Commented on byUro-Science.2022
Authors and funding
21 authors at 5 institutions in 2 countries.
Funding
Abstract
Autoimmune (AI) diseases can affect many organs; however, the prostate has not been considered to be a primary target of these systemic inflammatory processes. Here, we utilize medical record data, patient samples, and in vivo models to evaluate the impact of inflammation, as seen in AI diseases, on prostate tissue. Human and mouse tissues are used to examine whether systemic targeting of inflammation limits prostatic inflammation and hyperplasia. Evaluation of 112,152 medical records indicates that benign prostatic hyperplasia (BPH) prevalence is significantly higher among patients with AI diseases. Furthermore, treating these patients with tumor necrosis factor (TNF)-antagonists significantly decreases BPH incidence. Single-cell RNA-seq and in vitro assays suggest that macrophage-derived TNF stimulates BPH-derived fibroblast proliferation. TNF blockade significantly reduces epithelial hyperplasia, NFκB activation, and macrophage-mediated inflammation within prostate tissues. Together, these studies show that patients with AI diseases have a heightened susceptibility to BPH and that reducing inflammation with a therapeutic agent can suppress BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.